ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group.
| Autor: | Traversi L; Dept of Medicine and Surgery, Respiratory Diseases, Università dell'Insubria, Varese-Como, Italy.; Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain., Miravitlles M; Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain.; CIBER de Enfermedades Respiratorias, Barcelona, Spain., Martinez-Garcia MA; CIBER de Enfermedades Respiratorias, Barcelona, Spain.; Respiratory Dept, La Fe University and Polytechnic Hospital, Valencia, Spain., Shteinberg M; Pulmonology Institute and Cystic Fibrosis Center, Carmel Medical Center, and the Technion - Israel Institute of Technology, the B. Rappaport Faculty of Medicine, Haifa, Israel., Bossios A; Dept of Respiratory Medicine and Allergy, Karolinska University Hospital and Dept of Medicine, Karolinska Institutet, Stockholm, Sweden., Dimakou K; 5th Respiratory Department, 'SOTIRIA' Hospital for Chest diseases, Athens, Greece., Jacob J; Centre for Medical Image Computing, University College London, London, UK.; UCL Respiratory, University College London, London, UK., Hurst JR; UCL Respiratory, University College London, London, UK., Paggiaro PL; Dept of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy., Ferri S; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.; Dept of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Hillas G; 5th Respiratory Department, 'SOTIRIA' Hospital for Chest diseases, Athens, Greece., Vogel-Claussen J; Institute of Diagnostic and Interventional Radiology, German Center for Lung Research, Breath, Hannover Medical School, Hannover, Germany., Dettmer S; Institute of Diagnostic and Interventional Radiology, German Center for Lung Research, Breath, Hannover Medical School, Hannover, Germany., Aliberti S; Dept of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.; IRCCS Humanitas Research Hospital, Rozzano, Italy., Chalmers JD; IRCCS Humanitas Research Hospital, Rozzano, Italy.; School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK., Polverino E; Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ERJ open research [ERJ Open Res] 2021 Nov 22; Vol. 7 (4). Date of Electronic Publication: 2021 Nov 22 (Print Publication: 2021). |
| DOI: | 10.1183/23120541.00399-2021 |
| Abstrakt: | Introduction: The coexistence of COPD and bronchiectasis seems to be common and associated with a worse prognosis than for either disease individually. However, no definition of this association exists to guide researchers and clinicians. Methods: We conducted a Delphi survey involving expert pulmonologists and radiologists from Europe, Turkey and Israel in order to define the "COPD- [bronchiectasis] BE association".A panel of 16 experts from EMBARC selected 35 statements for the survey after reviewing scientific literature. Invited participants, selected on the basis of expertise, geographical and sex distribution, were asked to express agreement on the statements. Consensus was defined as a score of ≥6 points (scale 0 to 9) in ≥70% of answers across two scoring rounds. Results: 102 (72.3%) out of 141 invited experts participated in the first round. Their response rate in the second round was 81%. The final consensus definition of "COPD-BE association" was: "The coexistence of (1) specific radiological findings ( abnormal bronchial dilatation, airways visible within 1 cm of pleura and/or lack of tapering sign in ≥1 pulmonary segment and in >1 lobe) with (2) an obstructive pattern on spirometry ([forced expiratory volume in 1 s] FEV Conclusions: The Delphi process formulated a European consensus definition of "COPD-BE association". We hope this definition will have broad applicability across clinical practice and research in the future. Competing Interests: Conflict of interest: L. Traversi has nothing to disclose. Conflict of interest: M. Miravitlles reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon and CSL Behring, grants and personal fees from Grifols, personal fees from Novartis, grants and personal fees from GlaxoSmithKline, and personal fees from Gebro Pharma, Kamada, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, PH Pharma and from Sanofi, outside the submitted work. Conflict of interest: M.A. Martinez-Garcia reports personal fees from Grifols, grants and personal fees from TEVA, personal fees from Novartis and Zambon, grants and personal fees from Philips and Vitalair, and personal fees from Chiesi, AZ and GSK, outside the submitted work. Conflict of interest: M. Shteinberg reports grants and personal fees from GSK and Novartis, grants from Trudell Pharma, and personal fees from Actelion, Boehringer Ingelheim, Rafa, AstraZeneca, TEVA, Kamada, Horizon Pharma and Vertex pharmaceuticals, outside the submitted work. Conflict of interest: A. Bossios reports personal fees from GlaxoSmithKline, TEVA, Novartis, Sanofi and AstraZeneca outside the submitted work. Conflict of interest: K. Dimakou reports personal fees from Chiesi, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, GlaxoSmithKline and Menarini outside the submitted work. Conflict of interest: J. Jacob reports grants from Wellcome Trust Clinical Research Career Development, Roche, Boehringer Ingelheim, Novartis, GlaxoSmithKline and NHSX outside the submitted work. Conflict of interest: J.R. Hurst reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and Novartis outside the submitted work. Conflict of interest: P.L. Paggiaro reports personal fees from Alk-Abellò, AstraZeneca, Chiesi, GSK, Guidotti, Menarini, Mundipharma, Novartis and Sanofi outside the submitted work. Conflict of interest: S. Ferri has nothing to disclose. Conflict of interest: G. Hillas reports personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, ELPEN, Innovis, GSK, Menarini, Novartis, Pharmaten and UCB outside the submitted work. Conflict of interest: J. Vogel-Claussen reports grants and personal fees from Siemens Healthineers, AstraZeneca, GSK, Novartis and Boehringer Ingelheim outside the submitted work. Conflict of interest: S. Dettmer has nothing to disclose. Conflict of interest: S. Aliberti reports personal fees from Bayer Helthcare, Grifols, AstraZeneca and Zambon, grants and personal fees from Chiesi and INSMED, personal fees from GlaxoSmithKline, Menarini and ZetaCube Srl, and grants from Fisher & Paykel, outside the submitted work. Conflict of interest: J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi and GlaxoSmithKline, grants from Gilead Sciences, Novartis and Insmed, personal fees from Janssen and Zambon, and grants and personal fees from Grifols, outside the submitted work. Conflict of interest: E. Polverino reports personal fees from Bayer, grants and personal fees from Grifols, and personal fees from Insmed, Chiesi, Menarini, Zembon and Pfizer, outside the submitted work. (Copyright ©The authors 2021.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|